VA-ECMO后应用主动脉内球囊反搏降低心源性休克患者死亡率:中国体外生命支持注册登记分析
该研究基于中国体外生命支持注册登记(CSECLS),纳入2017年1月至2023年7月连续5492例接受VA-ECMO治疗的心源性休克患者,其中832例(15.1%)在VA-ECMO后接受IABP。主要终点为院内死亡率,IABP组为48.0%,未用IABP组为52.5%(P=0.017);多因素模型显示IABP与院内死亡风险降低相关(aOR 0.823,95%CI 0.686-0.987,P=0.035),但与机械、出血、肾脏及肺部并发症风险增加相关。作者认为IABP可能为VA-ECMO治疗的心源性休克患者提供左心室卸载优势,但需随机对照试验进一步验证风险与获益的平衡。
要点
- 在5492例VA-ECMO心源性休克患者中,15.1%(832例)在VA-ECMO后接受IABP,其院内死亡率为48.0%,未用IABP组为52.5%(P=0.017)。
- 多因素模型显示,VA-ECMO后使用IABP与院内死亡风险降低独立相关(aOR 0.823,95%CI 0.686-0.987,P=0.035),与支持中死亡风险降低相关(aOR 0.828,95%CI 0.688-0.995,P=0.044)。
- VA-ECMO后使用IABP与并发症风险增加相关:机械并发症aOR 1.905(95%CI 1.278-2.839,P=0.002)、出血aOR 1.371(95%CI 1.092-1.721,P=0.007)、肾脏并发症aOR 1.252(95%CI 1.041-1.505,P=0.017)、肺部并发症aOR 1.768(95%CI 1.446-2.163,P<0.001)。
- VA-ECMO前,IABP后使用组的心脏干预发生率(13.9% vs 16.7%)和心肌梗死发生率(12.0% vs 14.8%)均高于未用IABP组(均P<0.05)。
- 作者认为IABP可能为VA-ECMO治疗的心源性休克患者提供左心室卸载优势,但需随机对照试验进一步验证风险与获益的平衡。
适用人群与场景
- 2017年1月至2023年7月来自CSECLS注册登记的连续5492例接受VA-ECMO治疗的心源性休克患者,平均年龄54.7±15.1岁,男性3917例(71.3%)。
研究设计与关键结果
- 多中心回顾性研究,纳入CSECLS注册登记中2017年1月至2023年7月连续5492例VA-ECMO治疗的心源性休克患者,其中832例(15.1%)在VA-ECMO后接受IABP。
- 主要终点院内死亡率:IABP后使用组48.0% vs 未用IABP组52.5%(P=0.017);VA-ECMO支持中生存率:IABP后使用组79.4% vs 未用IABP组75.4%(P=0.014)。
- 多因素模型:VA-ECMO后使用IABP与院内死亡风险降低相关(aOR 0.823,95%CI 0.686-0.987,P=0.035),与支持中死亡风险降低相关(aOR 0.828,95%CI 0.688-0.995,P=0.044)。
- VA-ECMO后使用IABP与并发症风险增加相关:机械并发症aOR 1.905(95%CI 1.278-2.839,P=0.002)、出血aOR 1.371(95%CI 1.092-1.721,P=0.007)、肾脏并发症aOR 1.252(95%CI 1.041-1.505,P=0.017)、肺部并发症aOR 1.768(95%CI 1.446-2.163,P<0.001)。
- VA-ECMO前,IABP后使用组的心脏干预发生率(13.9% vs 16.7%)和心肌梗死发生率(12.0% vs 14.8%)均高于未用IABP组(均P<0.05)。
证据类型、等级与局限
- 证据类型:多中心回顾性研究。
- 局限:作者指出需随机对照试验进一步验证,以更好地理解风险与获益的平衡。
对床旁实践的改变
- 作者认为,VA-ECMO后使用IABP可能为心源性休克患者提供左心室卸载优势,但需随机对照试验进一步验证风险与获益的平衡。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The role of intra-aortic balloon pump (IABP) combined with venoarterial extracorporeal membrane oxygenation (VA-ECMO) in patients with cardiogenic shock (CS) remains unclear. This study investigated the effect of applying IABP for left ventricle (LV) unloading after VA-ECMO on reducing mortality in patients with CS.
METHODS: Data from 5,492 consecutive patients with CS treated with VA-ECMO between January 2017 and July 2023 were collected from the CSECLS registry. The primary outcome was in-hospital mortality. The secondary outcomes included 30-day mortality, survival on VA-ECMO, and various complications. The association between the application of IABP after VA-ECMO and in-hospital outcomes was assessed.
RESULTS: Among 5,492 patients undergoing VA-ECMO (mean age 54.7 ± 15.1 years, 3,917 [71.3%] male), 832 (15.1%) received IABP after VA-ECMO. Before VA-ECMO, a higher incidence of cardiac intervention (13.9% vs. 16.7%) and myocardial infarction (12.0% vs. 14.8%) (all P < 0.05) was seen in the IABP after VA-ECMO group. In this cohort, the IABP after VA-ECMO group had a lower in-hospital mortality (52.5% vs. 48.0%, P = 0.017) and a higher survival rate on VA-ECMO (75.4% vs. 79.4%, P = 0.014). On multivariate modeling, the use of IABP after VA-ECMO was associated with a lower risk of in-hospital mortality (adjusted odds ratio[aOR], 0.823 [95% confidence interval [CI], 0.686-0.987]; P = 0.035) and on-support mortality (aOR, 0.828 [95% CI, 0.688-0.995]; P = 0.044). However, the use of IABP after VA-ECMO was also associated with an increased incidence of complications, including mechanical (aOR: 1.905, [95% CI, 1.278-2.839]; P = 0.002), bleeding (aOR: 1.371, [95% CI, 1.092-1.721]; P = 0.007), renal (aOR: 1.252, [95% CI, 1.041-1.505]; P = 0.017), and pulmonary (aOR: 1.768, [95% CI, 1.446-2.163]; P < 0.001).
CONCLUSION: In this multicenter retrospective study, the use of IABP after VA-ECMO was associated with lower in-hospital mortality in patients with CS. These findings suggest that IABP may offer advantages for LV unloading in patients with CS treated with VA-ECMO, but further validation through randomized controlled trials is warranted to better understand the balance of risks and benefits.
参考来源
- Wang K, Wang L, Ma J, et al. Intra-aortic balloon pump after VA-ECMO reduces mortality in patients with cardiogenic shock: an analysis of the Chinese extracorporeal life support registry. Crit Care. 2024. PMID: 39614333. doi:10.1186/s13054-024-05129-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。